AI‐guided histopathology predicts brain metastasis in lung cancer patients
Abstract
Brain metastases can occur in nearly half of patients with early and locally advanced (stage I–III) non-small cell lung cancer (NSCLC). There are no reliable histopathologic or molecular means to identify those who are likely to develop brain metastases. We sought to determine if deep learning (DL) could be applied to routine H&E-stained primary tumor tissue sections from stage I–III NSCLC patients to predict the development of brain metastasis. Diagnostic slides from 158 patients with stage I–III NSCLC followed for at least 5 years for the development of brain metastases (Met+, 65 patients) versus no progression (Met−, 93 patients) were subjected to whole-slide imaging. Three separate iterations were performed by first selecting 118 cases (45 Met+, 73 Met−) to train and validate the DL algorithm, while 40 separate cases (20 Met+, 20 Met−) were used as the test set. The DL algorithm results were compared to a blinded review by four expert pathologists. The DL-based algorithm was able to distinguish the eventual development of brain metastases with an accuracy of 87% (p < 0.0001) compared with an average of 57.3% by the four pathologists and appears to be particularly useful in predicting brain metastases in stage I patients. The DL algorithm appears to focus on a complex set of histologic features. DL-based algorithms using routine H&E-stained slides may identify patients who are likely to develop brain metastases from those who will remain disease free over extended (>5 year) follow-up and may thus be spared systemic therapy.
Copyright and License
© 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Acknowledgement
This study was supported by U01CA233363 and by the Washington University in St. Louis School of Medicine Personalized Medicine Initiative (RJC). HZ, SL, SM and CY are supported by Sensing to Intelligence (S2I) (grant no. 13520296) and Heritage Research Institute for the Advancement of Medicine and Science at Caltech (grant no. HMRI-15-09-01). MW and RG were supported by the National Cancer Institute (grant no. 5R01CA182746).
Contributions
HZ and MW wrote the first draft of the paper. RJC, CY, HZ and MW conceived the experimental design. HZ, SL, SM and CY performed the DL and data analysis in this study. MW, CTB, SR and RJC designed the clinical and pathologic section of the experiments. CTB, CL, JHR and AW provided the clinical evaluation. MW, RG and RJC provided essential data resources. HZ, MW, CTB, SL, SM, SR, RG, CY and RJC contributed to the writing of this paper.
Data Availability
The data that support the findings of this study are openly available in CaltechData at https://doi.org/10.22002/dw66e-mbs82. The code for processing the data is publicly available on GitHub at https://github.com/hwzhou2020/NSCLC_ResNet.
Files
Name | Size | Download all |
---|---|---|
md5:4209acf669a67a82927893da479cca49
|
9.7 MB | Preview Download |
md5:ee38d35e2dced5163baeea2e353df6fb
|
793.8 kB | Download |
Additional details
- ISSN
- 1096-9896
- DOI
- 10.1002/path.6263
- PMCID
- PMC11210939
- National Institutes of Health
- U01CA233363
- California Institute of Technology
- Center for Sensing to Intelligence (S2I) 13520296
- California Institute of Technology
- Heritage Medical Research Institute HMRI-15-09-01
- National Institutes of Health
- 5R01CA182746
- Caltech groups
- Heritage Medical Research Institute, Caltech Center for Sensing to Intelligence (S2I)